abstracts poster abstracts - falk-foundation- abstracts/poster abstracts falk symposium 200...

Download Abstracts Poster Abstracts - falk-foundation- Abstracts/Poster Abstracts Falk Symposium 200 Abstracts

If you can't read please download the document

Post on 06-Jan-2020

2 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • A b

    st ra

    ct s/

    Po st

    er A

    b st

    ra ct

    s Fa

    lk S

    ym p

    o si

    u m

    2 00

    Abstracts Poster Abstracts

    Falk Foundation Dr. Falk Pharma

    Abstracts Poster Abstracts

    Falk Symposium 200

    Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond

    October 16 – 17, 2015 Konzerthaus Freiburg Freiburg, Germany

    115308_Falk_Freiburg_Symp_200_Abstracts_US.indd 1 21.09.15 08:39

  • www.falkfoundation.org

    © 2015 Falk Foundation e.V. All rights reserved.

    FALK FOUNDATION e.V. Leinenweberstr. 5 79108 Freiburg Germany

    115308_Falk_Freiburg_Symp_200_Abstracts_US.indd 2 21.09.15 08:39

  • Abstracts of Invited Lectures Poster Abstracts

    Falk Symposium 200

    THERAPEUTIC STRATEGIES IN DISEASES OF THE DIGESTIVE TRACT – 2015 AND BEYOND

    Freiburg, Germany October 16 – 17, 2015

    Scientific Organization: M.J. Bruno, Rotterdam (The Netherlands) E.M. El-Omar, Aberdeen (Scotland) P. Ginès, Barcelona (Spain) D.K. Podolsky, Dallas (USA) J. Schölmerich, Frankfurt (Germany)

  • 3

    CONTENTS

    page Session I

    Esophagus

    Chair: C. Ell, Offenbach T. Matysiak-Budnik, Nantes

    Eosinophilic esophagitis: Not just for children A. Schoepfer, Lausanne 19

    Endoscopic management of early cancer R.E. Pouw, Amsterdam 20

    Achalasia: From bench to POEMs G.E. Boeckxstaens, Leuven 21

    State-of-the-Art Lecture From reflux to cancer R.F. Souza, Dallas 22

    Session II

    Stomach

    Chair: E.M. El-Omar, Aberdeen P. Malfertheiner, Magdeburg

    Functional dyspepsia and gastroparesis M. Camilleri, Rochester 25

    Stategies for prevention of gastric cancer: Progress from mass eradication trials K. Sugano, Tochigi 26

    Failed eradication of Helicobacter pylori: What should be done? F. Mégraud, Bordeaux 27

    State-of-the-Art Lecture New biology to new treatment of gastric cancer R.M. Peek, Jr., Nashville 28

  • 4

    Presentation of the Hans Popper Award M.P. Manns, Hanover

    Hans Popper Award Lecture Cholestatic and autoimmune liver diseases – From genetics to environment and back T.H. Karlsen, Oslo 29

    Session III

    Pancreas

    Chair: M.J. Bruno, Rotterdam T. Gress, Marburg

    Decision making in necrotizing pancreatitis T. Hackert, M.W. Büchler, Heidelberg 33 – 34

    Development of pancreatic cancer: Targets for early detection and treatment M.M. Lerch, Greifswald 35 – 37

    Autoimmune pancreatitis: A riddle wrapped in an enigma G. Webster, London 38

    State-of-the-Art Lecture Improving the outcome of acute pancreatitis: Current guidelines and beyond M.J. Bruno, Rotterdam 39

    Session IV

    Systemic disorders and systemic approaches in the digestive tract

    Chair: A. Dignass, Frankfurt Y. Liu, Beijing

    Gut and liver in vasculitic disorders U. Müller-Ladner, Bad Nauheim 43

    Gut and liver in sepsis C. Trautwein, Aachen 44

  • 5

    Five genetic disorders a gastroenterologist should know J. Cho, New York 45

    Molecular imaging as a basis of treatment R. Atreya, Erlangen 46

    State-of-the-Art Lecture Microbiota as therapeutic targets R.J. Xavier, Boston 47

    Presentation of Poster Prizes P. Ginès, Barcelona

    Session V

    Small and large bowel

    Chair: D.K. Podolsky, Dallas G. Rogler, Zurich

    IBS: More than motility J. Tack, Leuven 51

    Therapeutic approaches in IBD beyond the immuno- suppressive paradigm J. Wehkamp, Tübingen 52

    Targeted therapies in colon cancer today and tomorrow W. Schmiegel, Bochum 53

    Endoscopy beyond visible light as basis of treatment M. Götz, Tübingen 54

    State-of-the-Art Lecture Building a better human intestine M.A. Helmrath, Cincinnati 55

    Session VI

    Liver and biliary system

    Chair: J. Schölmerich, Frankfurt S. Zeuzem, Frankfurt

    FXR agonists for liver disease M. Trauner, Wien 59 – 61

  • 6

    Treatment of liver fibrosis D.A. Brenner, La Jolla 62

    Treatment of hepatocellular carcinoma J. Bruix, Barcelona 63

    State-of-the-Art Lecture Hepatology after hepatitis C J.G. Fitz, Dallas 64

    List of Chairpersons, Speakers and Scientific Organizers 65 – 68

  • 7

    Poster Abstracts

    1. Serotonin: A marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? H.A. Abd el Moety, D.A. Maharem, S.H. Gomaa (Alexandria, EG)

    2. Malnutrition prevalence among patients with liver cirrhosis in relation to the duration of cirrhosis history A. Adamenka (Minsk, BY)

    3. Evaluation of the Lavandula stoechas L. extract in the experimental model of irritable bowel syndrome induced by acetic acid F. Algieri, A. Rodriguez-Nogales, T. Vezza, M.P. Utrilla, O. Banuelos, M.R. Gonzalez-Tejero, M. Casares-Porcel, J. Molero-Mesa, M.E. Rodriguez- Cabezas, J. Galvez (Granada, ES)

    4. Single-centre clinical experience of Hemospray endotherapy in patients with acute upper gastrointestinal bleeding A. Alisa (London, GB)

    5. Development and validation of a new disease severity index: The inflammatory bowel disease index (IBDex®) L. Alrubaiy, P. Dodds, H.A. Hutchings, I.T. Russell, A. Watkins, J.G. Williams (Swansea, GB)

    6. The Crohn's and ulcerative colitis questionnaire-12 (CUCQ-12): A short quality of life tool for inflammatory bowel disease L. Alrubaiy, H.A. Hutchings, A. Protheroe, K. Mortier, J.G. Williams (Swansea, London, GB)

    7. Comparison of affective temperament profile between patients with irritable bowel syndrome and healthy controls K. Altinbas, E. Akbal, F. Günes (Canakkale, TR)

    8. Two-week protein-enriched low-calorie diet (HEPAFAST) shows rapid improve- ment of fatty liver as assessed by controlled attenuation parameter A. Arslanow, M. Teutsch, H. Walle, F. Lammert, C.S. Stokes (Homburg, Kirkel, DE)

    9. Primary colon involvement in non-Hodgkin lymphomas D. Badea, M. Badea, A.-M. Genunche-Dumitrescu, P. Mitrut, A. Badea (Craiova, RO)

    10. Therapeutic approach in primary indolent gastrointestinal lymphoma M. Badea, D. Badea, A.-M. Genunche-Dumitrescu, P. Mitrut, A. Badea, D. Duta (Craiova, RO)

    11. Loss of integrin β6 (ITGB6) protects from colon cancer development in vivo S. Bengs, M.R. Spalinger, S. Kasper, S. Lang, I. Frey-Wagner, K. Atrott, A. Weber, G. Rogler, M. Scharl (Zurich, CH)

  • 8

    12. Loss of integrin β6 (ITGB6) results in aggravated acute and chronic DSS-in- duced colitis S. Bengs, M.R. Spalinger, S. Kasper, S. Lang, I. Frey-Wagner, K. Atrott, A. Weber, G. Rogler, M. Scharl (Zurich, CH)

    13. Diagnosis and treatment management in digestive-cutaneous purpura in young patients M.C. Bezna, C. Deliu, M. Bezna, C. Pitis (Craiova, RO)

    14. Mesalazine-induced thrombocytopenia and pericarditis in paediatric inflam- matory bowel disease T. Bhaduri, B. Bhaduri (London, Maidstone, GB)

    15. MiR-155 plays a central role in Th17 cell development and in the pathogenesis of intestinal inflammation T. Bormann, I. Backert, C. Neufert, M.F. Neurath, S.J. Wirtz, M.J. Waldner (Erlangen, DE)

    16. Viral modulation of extrinsic cell death pathways B. Buchen, C. Günther, V. Murtadak, M. Stürzl, E. Cesarman, G. Ballon, M.F. Neurath, C. Becker (Erlangen, DE; New York, US)

    17. ERAP1 gene polymorphisms in Turkish patients with inflammatory bowel disease and ankylosing spondylitis H. Cetinkaya, C. Kalkan, M.F. Karakaya, A. Caliskan Kartal, O. Küküksahin, M. Bektas, A.I. Soykan, K. Bahar, M. Törüner, A.E. Tüzün (Ankara, TR)

    18. Treatment of dysbiosis in uncomplicated diverticular disease of the colon I. Copaci, M. Mihaila, G. Chiriac, L. Micu, G. Constantinescu (Bucharest, RO)

    19. Extra-colonic cancer risk in collagenous colitis K.J. Dabos, J. Larsson, A. Giannakou, A. Nemeth, G. Wurm-Johansson, K. Sjoberg, E. Toth, J.N. Plevris, A. Koulaouzidis (Edinburgh, GB; Malmö, SE; Nicosia, CY)

    20. Clinical-biological particularities of non-alcoholic fatty liver disease in Romanian patients D.N. Dascalu (Sibiu, RO)

    21. Infliximab or adalimumab for Crohn's disease M. Dranga, C. Mihai, O. Gavrilescu, A.-M. Chiosa, A. Didita, M.A. Badea, C. Cijevschi Prelipcean (Iasi, RO)

    22. Prevalence of celiac disease in patients with cystic hydatid disease: May they have been related to same environmental conditions? A.C. Dülger, H. Güdücüoglu, Y.E. Beyhan, Z.T. Cengiz, M. Aydin, B. Suvak, B. Gültepe (Van, Istanbul, TR)

  • 9

    23. Intestinal anti-inflammatory effects of total alkaloids of Fumaria capreolata in the DNBS model of mice colitis J. Galvez, N. Bribi, A. Rodriguez-Nogales, F. Algieri, T. Vezza, J. Garrido-Mesa, M.P. Utrilla, F. Maiza, M. Del Mar Contreras, A. Segura-Carretero, M.E. Rodriguez-Cabezas (Bejaia, DZA; Granada, ES)

    24. The antidepressant agomelatine reduces intestinal inflammation in DNBS experimental colitis in mice J. Garrido-Mesa, A. Rodriguez-Nogales, F. Algieri, T. Vezza, M.P. Utrilla, M.E. Rodriguez-Cabezas, J. Leon, J. Salmeron, J. Galvez (Granada, ES)

    25. Pentoxifylline and prednisone versus prednisolone for severe alcoholic hepatitis O. Gavrilescu, C. Mihai, M. Dranga, A.-M. Chiosa, A. Didita, M.A. Badea, C. Cijevschi Prelipcean (Iasi, RO)

    26. Medical history of eradicated Helicobacter pylori infection as an individual risk factor for gastric cancer A.-M. Genunche-Dumitrescu, D. Badea, M. Bad

Recommended

View more >